Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 64 CHF -0.78% Market Closed
Market Cap: 1B CHF
Have any thoughts about
Cosmo Pharmaceuticals NV?
Write Note

Intrinsic Value

The intrinsic value of one COPN stock under the Base Case scenario is 140.15 CHF. Compared to the current market price of 64 CHF, Cosmo Pharmaceuticals NV is Undervalued by 54%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

COPN Intrinsic Value
140.15 CHF
Undervaluation 54%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cosmo Pharmaceuticals NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for COPN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about COPN?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Cosmo Pharmaceuticals NV

Provide an overview of the primary business activities
of Cosmo Pharmaceuticals NV.

What unique competitive advantages
does Cosmo Pharmaceuticals NV hold over its rivals?

What risks and challenges
does Cosmo Pharmaceuticals NV face in the near future?

Has there been any significant insider trading activity
in Cosmo Pharmaceuticals NV recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cosmo Pharmaceuticals NV.

Provide P/S
for Cosmo Pharmaceuticals NV.

Provide P/E
for Cosmo Pharmaceuticals NV.

Provide P/OCF
for Cosmo Pharmaceuticals NV.

Provide P/FCFE
for Cosmo Pharmaceuticals NV.

Provide P/B
for Cosmo Pharmaceuticals NV.

Provide EV/S
for Cosmo Pharmaceuticals NV.

Provide EV/GP
for Cosmo Pharmaceuticals NV.

Provide EV/EBITDA
for Cosmo Pharmaceuticals NV.

Provide EV/EBIT
for Cosmo Pharmaceuticals NV.

Provide EV/OCF
for Cosmo Pharmaceuticals NV.

Provide EV/FCFF
for Cosmo Pharmaceuticals NV.

Provide EV/IC
for Cosmo Pharmaceuticals NV.

Show me price targets
for Cosmo Pharmaceuticals NV made by professional analysts.

What are the Revenue projections
for Cosmo Pharmaceuticals NV?

How accurate were the past Revenue estimates
for Cosmo Pharmaceuticals NV?

What are the Net Income projections
for Cosmo Pharmaceuticals NV?

How accurate were the past Net Income estimates
for Cosmo Pharmaceuticals NV?

What are the EPS projections
for Cosmo Pharmaceuticals NV?

How accurate were the past EPS estimates
for Cosmo Pharmaceuticals NV?

What are the EBIT projections
for Cosmo Pharmaceuticals NV?

How accurate were the past EBIT estimates
for Cosmo Pharmaceuticals NV?

Compare the revenue forecasts
for Cosmo Pharmaceuticals NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cosmo Pharmaceuticals NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cosmo Pharmaceuticals NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cosmo Pharmaceuticals NV compared to its peers.

Compare the P/E ratios
of Cosmo Pharmaceuticals NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Cosmo Pharmaceuticals NV with its peers.

Analyze the financial leverage
of Cosmo Pharmaceuticals NV compared to its main competitors.

Show all profitability ratios
for Cosmo Pharmaceuticals NV.

Provide ROE
for Cosmo Pharmaceuticals NV.

Provide ROA
for Cosmo Pharmaceuticals NV.

Provide ROIC
for Cosmo Pharmaceuticals NV.

Provide ROCE
for Cosmo Pharmaceuticals NV.

Provide Gross Margin
for Cosmo Pharmaceuticals NV.

Provide Operating Margin
for Cosmo Pharmaceuticals NV.

Provide Net Margin
for Cosmo Pharmaceuticals NV.

Provide FCF Margin
for Cosmo Pharmaceuticals NV.

Show all solvency ratios
for Cosmo Pharmaceuticals NV.

Provide D/E Ratio
for Cosmo Pharmaceuticals NV.

Provide D/A Ratio
for Cosmo Pharmaceuticals NV.

Provide Interest Coverage Ratio
for Cosmo Pharmaceuticals NV.

Provide Altman Z-Score Ratio
for Cosmo Pharmaceuticals NV.

Provide Quick Ratio
for Cosmo Pharmaceuticals NV.

Provide Current Ratio
for Cosmo Pharmaceuticals NV.

Provide Cash Ratio
for Cosmo Pharmaceuticals NV.

What is the historical Revenue growth
over the last 5 years for Cosmo Pharmaceuticals NV?

What is the historical Net Income growth
over the last 5 years for Cosmo Pharmaceuticals NV?

What is the current Free Cash Flow
of Cosmo Pharmaceuticals NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cosmo Pharmaceuticals NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cosmo Pharmaceuticals NV

Current Assets 183.6m
Cash & Short-Term Investments 133.4m
Receivables 36.3m
Other Current Assets 13.9m
Non-Current Assets 454.7m
Long-Term Investments 3.2m
PP&E 27.4m
Intangibles 398.5m
Other Non-Current Assets 25.7m
Current Liabilities 37.9m
Accounts Payable 14.7m
Accrued Liabilities 5.3m
Other Current Liabilities 18m
Non-Current Liabilities 101.9m
Long-Term Debt 714k
Other Non-Current Liabilities 101.2m
Efficiency

Earnings Waterfall
Cosmo Pharmaceuticals NV

Revenue
189.3m EUR
Cost of Revenue
-43.6m EUR
Gross Profit
145.7m EUR
Operating Expenses
-53.6m EUR
Operating Income
92.1m EUR
Other Expenses
-16.4m EUR
Net Income
75.7m EUR

Free Cash Flow Analysis
Cosmo Pharmaceuticals NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

COPN Profitability Score
Profitability Due Diligence

Cosmo Pharmaceuticals NV's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
69/100
Profitability
Score

Cosmo Pharmaceuticals NV's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

COPN Solvency Score
Solvency Due Diligence

Cosmo Pharmaceuticals NV's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Cosmo Pharmaceuticals NV's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

COPN Price Targets Summary
Cosmo Pharmaceuticals NV

Wall Street analysts forecast COPN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for COPN is 97.72 CHF with a low forecast of 79.79 CHF and a high forecast of 139.65 CHF.

Lowest
Price Target
79.79 CHF
25% Upside
Average
Price Target
97.72 CHF
53% Upside
Highest
Price Target
139.65 CHF
118% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for COPN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for COPN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

COPN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV

Country

Ireland

Industry

Pharmaceuticals

Market Cap

1B CHF

Dividend Yield

3.13%

Description

Cosmo Pharmaceuticals NV engages in the development, manufacturing, and distribution of treatments for gastrointestinal diseases, endoscopy, colorectal cancer diagnosis, and colonoscopy. The company is headquartered in Dublin, Dublin and currently employs 290 full-time employees. The company went IPO on 2016-05-18. The firm develops therapies for gastrointestinal disorders. The firm's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. The company has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.

Contact

DUBLIN
DUBLIN
Riverside II, Sir John Rogerson's Quay
+35318170370.0
www.cosmopharma.com

IPO

2016-05-18

Employees

290

Officers

Executive Chairman
Mr. Alessandro E. Della Cha LL.M
Executive Director & CFO
Mr. Niall Donnelly
Chief Executive Officer & Director
Mr. Giovanni Di Napoli
Founder & Non-Executive Director
Mr. Mauro Severino Ajani
Chief Operating Officer
Mr. Marco Lecchi
Qualified Person & Technical Director
Mr. Davide Malavasi
Show More
Chief Scientific Officer
Mr. Luigi Longo
Head of Investor Relations
Ms. Hazel Winchester
Chief People Officer
Mr. Biagio Vigano
Chief Manufacturing Officer
Mr. Roberto Villa
Show Less

See Also

Discover More
What is the Intrinsic Value of one COPN stock?

The intrinsic value of one COPN stock under the Base Case scenario is 140.15 CHF.

Is COPN stock undervalued or overvalued?

Compared to the current market price of 64 CHF, Cosmo Pharmaceuticals NV is Undervalued by 54%.

Back to Top